MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

MC

543.5

-5.36%↓

SANES

6.042

-5%↓

BNP

73.98

-4.74%↓

CS.FR

39.63

-1.74%↓

ALV

353.7

-0.79%↓

Search

DBV Technologies SA

Închisă

1.336 8.62

Rezumat

Modificarea prețului

24h

Curent

Minim

1

Maxim

1.374

Indicatori cheie

By Trading Economics

Venit

2.7M

-30M

EPS

-0.288

Marjă de profit

-2,852.369

EBITDA

5.1M

-29M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+376.19% upside

Dividende

By Dow Jones

Următoarele câștiguri

10 apr. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

118M

Deschiderea anterioară

-7.28

Închiderea anterioară

1.336

Scor tehnic

By Trading Central

Încredere

Very Strong Bullish Evidence

DBV Technologies SA Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

11 dec. 2024, 23:55 UTC

Acțiuni populare

Stocks to Watch: Adobe, Champions Oncology, DBV Technologies

22 oct. 2024, 21:37 UTC

Principalele dinamici ale pieței

DBV Technologies Rally 47% Following Positive Updates for Peanut Allergy Patch

Comparație

Modificare preț

DBV Technologies SA Așteptări

Obiectiv de preț

By TipRanks

376.19% sus

Prognoză pe 12 luni

Medie 6 EUR  376.19%

Maxim 6 EUR

Minim 6 EUR

În baza a 1 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruDBV Technologies SA - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

1 ratings

1

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

0.784 / 1.31Suport & Rezistență

Termen scurt

Very Strong Bullish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Strong Bullish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre DBV Technologies SA

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.